Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported fourth-quarter 2025 results showing continued commercial uptake of its lead product Rezdiffra (resmetirom), with…
Temperature-controlled logistics leader posts fourth-quarter AFFO of $0.38 per share despite revenue contraction and widening net loss. Management sets 2026…